Table 4.
The association between the use of cardiac drug therapies and symptoms of anxiety
| Model 1a | Model 2b | Model 3c | |
|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| HADS-A ≥ 8 n = 2891 | |||
| Diuretics | 1.12 (1.03; 1.23)* | 1.18 (1.07; 1.31)* | 1.14 (1.02; 1.28)* |
| Lipid-lowering agents | 1.17 (1.06; 1.30)* | 1.27 (1.12; 1.44)* | 1.19 (1.05; 1.36)* |
| Aspirin | 1.11 (1.01; 1.23)* | 1.16 (1.03; 1.30)* | 1.10 (0.96; 1.25) |
| Anticoagulants | 0.93 (0.79; 1.11) | 1.19 (0.99; 1.44) | 0.93 (0.75; 1.14) |
| Aldosterone antagonists | 1.04 (0.93; 1.16) | 1.02 (0.90; 1.16) | 0.91 (0.79; 1.04) |
| Nitrates | 1.29 (1.18; 1.41)* | 1.30 (1.17; 1.44)* | 1.26 (1.13; 1.40)* |
| Antiarrhythmics | 1.13 (1.01; 1.28)* | 1.27 (1.12; 1.44)* | 1.25 (1.10; 1.43)* |
| Digoxin | 1.05 (0.93; 1.20) | 1.13 (0.98; 1.29) | 1.10 (0.95; 1.26) |
| Angiotensin receptor antagonists | 1.06 (0.96; 1.18) | 1.08 (0.97; 1.20) | 1.04 (0.98; 1.16) |
| ACE-inhibitors | 0.99 (0.91; 1.08) | 1.02 (0.93; 1.12) | 0.98 (0.88; 1.08) |
| Beta-blockers | 1.16 (1.04; 1.31)* | 1.23 (1.09; 1.39)* | 1.14 (1.01; 1.29)* |
*Statistically significant association
aMultivariable logistic regression model unadjusted
bMultivariable logistic regression model adjusted for age, sex, TU-comorbidity index score and diagnostic group
cMultivariable logistic regression model adjusted for age, sex, TU-comorbidity index score, diagnostic group, cardiac drug group and psychotropic medication